May Hill Capital LLC Buys New Holdings in Haemonetics Co. (NYSE:HAE)

May Hill Capital LLC bought a new position in shares of Haemonetics Co. (NYSE:HAE) during the fourth quarter, Holdings Channel.com reports. The fund bought 17,915 shares of the medical instruments supplier’s stock, valued at approximately $1,399,000.

A number of other large investors also recently modified their holdings of HAE. FMR LLC increased its holdings in Haemonetics by 206.3% during the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock worth $62,257,000 after purchasing an additional 521,640 shares in the last quarter. Norges Bank bought a new stake in Haemonetics during the fourth quarter worth $32,803,000. Wellington Management Group LLP grew its holdings in Haemonetics by 9.5% during the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock worth $337,722,000 after buying an additional 363,702 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Haemonetics in the 4th quarter valued at $19,002,000. Finally, Thrivent Financial for Lutherans lifted its stake in Haemonetics by 14.9% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier’s stock valued at $98,716,000 after acquiring an additional 164,111 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Stock Up 0.7 %

Haemonetics stock opened at $63.65 on Tuesday. The firm has a 50 day simple moving average of $65.85 and a 200 day simple moving average of $74.63. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 1-year low of $58.80 and a 1-year high of $97.97. The firm has a market capitalization of $3.20 billion, a price-to-earnings ratio of 25.06, a P/E/G ratio of 1.11 and a beta of 0.43.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current year.

Analyst Ratings Changes

HAE has been the topic of a number of recent analyst reports. JMP Securities dropped their price target on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research report on Friday, February 7th. Barrington Research dropped their price target on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Raymond James restated a “strong-buy” rating and issued a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. Finally, Bank of America downgraded shares of Haemonetics from a “neutral” rating to an “underperform” rating and cut their price target for the stock from $95.00 to $68.00 in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $101.22.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.